Belite Bio (BLTE) Stock Forecast, Price Target & Predictions
BLTE Stock Forecast
Belite Bio stock forecast is as follows: an average price target of $60.00 (represents a -27.13% downside from BLTE’s last price of $82.34) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BLTE Price Target
The average price target for Belite Bio (BLTE) is $60.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $60.00. This represents a potential -27.13% downside from BLTE's last price of $82.34.
BLTE Analyst Ratings
According to 1 Wall Street analysts, Belite Bio's rating consensus is 'Buy'. The analyst rating breakdown for BLTE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Belite Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Yi Chen | H.C. Wainwright | $60.00 | $48.55 | 23.58% | -27.13% |
The latest Belite Bio stock forecast, released on Aug 13, 2024 by Yi Chen from H.C. Wainwright, set a price target of $60.00, which represents a 23.58% increase from the stock price at the time of the forecast ($48.55), and a -27.13% decrease from BLTE last price ($82.34).
Belite Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $60.00 |
| Last Closing Price | $82.34 | $82.34 | $82.34 |
| Upside/Downside | -100.00% | -100.00% | -27.13% |
In the current month, the average price target of Belite Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Belite Bio's last price of $82.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Belite Bio's last stock rating was published by H.C. Wainwright on Sep 12, 2024. The company gave BLTE a "Buy" rating, the same as its previous rate.
Belite Bio Financial Forecast
Belite Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $16.67M | - | - |
| High Forecast | - | - | - | - | $16.67M | - | - |
| Low Forecast | - | - | - | - | $16.67M | - | - |
| # Analysts | - | - | - | - | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - |
Belite Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BLTE's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Belite Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict BLTE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Belite Bio's previous annual EBITDA (undefined) of $NaN.
Belite Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-10.64M | $-9.51M | $-10.84M | $-10.84M | $-9.88M | $-8.84M | $-7.76M |
| High Forecast | $-10.64M | $-9.51M | $-10.84M | $-10.84M | $-9.01M | $-8.84M | $-7.76M |
| Low Forecast | $-10.64M | $-9.51M | $-10.84M | $-10.84M | $-10.46M | $-8.84M | $-7.76M |
| Surprise % | - | - | - | - | - | - | - |
Belite Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BLTE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Belite Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Belite Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to BLTE last annual SG&A of $NaN (undefined).
Belite Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | May 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.35 | $-0.31 | $-0.35 | $-0.35 | $-0.32 | $-0.29 | $-0.26 |
| High Forecast | $-0.35 | $-0.31 | $-0.35 | $-0.35 | $-0.29 | $-0.29 | $-0.26 |
| Low Forecast | $-0.35 | $-0.31 | $-0.35 | $-0.35 | $-0.34 | $-0.29 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Belite Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BLTE previous annual EPS of $NaN (undefined).
Belite Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.59 | $18.00 | 1032.08% | Buy |
| IMRX | Immuneering | $2.04 | $17.50 | 757.84% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| MOLN | Molecular Partners | $5.46 | $29.00 | 431.14% | Buy |
| AVTE | Aerovate Therapeutics | $2.67 | $13.00 | 386.89% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| VIGL | Vigil Neuroscience | $3.04 | $11.00 | 261.84% | Buy |
| ACRV | Acrivon Therapeutics | $6.38 | $21.83 | 242.16% | Buy |
| LRMR | Larimar Therapeutics | $6.38 | $20.33 | 218.65% | Buy |
| ANAB | AnaptysBio | $19.97 | $52.00 | 160.39% | Buy |
| CELC | Celcuity | $12.47 | $31.50 | 152.61% | Buy |
| MLYS | Mineralys Therapeutics | $12.86 | $30.00 | 133.28% | Buy |
| ADAG | Adagene | $2.22 | $5.00 | 125.23% | Buy |
| GLTO | Galecto | $5.90 | $10.00 | 69.49% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.83 | $23.25 | 38.15% | Buy |
| TRDA | Entrada Therapeutics | $17.77 | $20.00 | 12.55% | Buy |
| IKNA | Ikena Oncology | $1.68 | $1.33 | -20.83% | Buy |
| AADI | Aadi Bioscience | $2.21 | $1.63 | -26.24% | Hold |
| BLTE | Belite Bio | $82.34 | $60.00 | -27.13% | Buy |
| ALGS | Aligos Therapeutics | $18.50 | $3.00 | -83.78% | Hold |